SVB Securities Reaffirms Their Buy Rating on Vir Biotechnology (VIR)

SVB Securities analyst Roanna Ruiz reiterated a Buy rating on Vir Biotechnology (VIRResearch Report) on February 3 and set a price target of $43.00. The company’s shares closed last Friday at $30.14.

According to TipRanks, Ruiz is an analyst with an average return of -29.5% and a 29.51% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Lantheus, Enanta Pharmaceuticals, and Vir Biotechnology.

In addition to SVB Securities, Vir Biotechnology also received a Buy from Needham’s Joseph Stringer in a report issued on January 25. However, on January 27, Morgan Stanley upgraded Vir Biotechnology (NASDAQ: VIR) to a Hold.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $34.97 and a one-year low of $18.05. Currently, Vir Biotechnology has an average volume of 832.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.

Read More on VIR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More